- Home
- DTIL vs LUNG Comparison
DTIL vs LUNG Comparison
Compare DTIL & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- LUNG
- Stock Information
- Founded
- DTIL 2006
- LUNG 1995
- Country
- DTIL United States
- LUNG United States
- Employees
- DTIL N/A
- LUNG N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- LUNG Industrial Specialties
- Sector
- DTIL Health Care
- LUNG Health Care
- Exchange
- DTIL Nasdaq
- LUNG Nasdaq
- Market Cap
- DTIL 55.3M
- LUNG 65.6M
- IPO Year
- DTIL 2019
- LUNG 2020
- Fundamental
- Price
- DTIL $5.44
- LUNG $1.84
- Analyst Decision
- DTIL Strong Buy
- LUNG Buy
- Analyst Count
- DTIL 2
- LUNG 7
- Target Price
- DTIL $47.00
- LUNG $7.66
- AVG Volume (30 Days)
- DTIL 93.0K
- LUNG 339.3K
- Earning Date
- DTIL 11-03-2025
- LUNG 10-29-2025
- Dividend Yield
- DTIL N/A
- LUNG N/A
- EPS Growth
- DTIL N/A
- LUNG N/A
- EPS
- DTIL N/A
- LUNG N/A
- Revenue
- DTIL $1,261,000.00
- LUNG $90,549,000.00
- Revenue This Year
- DTIL N/A
- LUNG $10.30
- Revenue Next Year
- DTIL $135.19
- LUNG $14.72
- P/E Ratio
- DTIL N/A
- LUNG N/A
- Revenue Growth
- DTIL N/A
- LUNG 18.24
- 52 Week Low
- DTIL $3.61
- LUNG $1.47
- 52 Week High
- DTIL $9.81
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- DTIL 62.03
- LUNG 55.92
- Support Level
- DTIL $5.26
- LUNG $1.69
- Resistance Level
- DTIL $5.56
- LUNG $1.96
- Average True Range (ATR)
- DTIL 0.22
- LUNG 0.11
- MACD
- DTIL 0.06
- LUNG 0.02
- Stochastic Oscillator
- DTIL 88.68
- LUNG 71.43
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.